Drugs / GAP T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02932956 | Dec 2018 → Sep 2021 overdue | liver cancer | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GAP T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02932956 ↗ |
| Action | Deplete | “they can put a new gene into T cells that will make them recognize cancer cells and kill them.” NCT02932956 ↗ |
| Modality | Cell therapy | “This study will test T cells genetically engineered with a GPC3-CAR (GAP T cells)” NCT02932956 ↗ |
| Route | Other | “the cells will be thawed and injected into the patient over 5 to 10 minutes” NCT02932956 ↗ |
| Target | GPC3 | “an antibody called GC33 that recognizes glypican-3, a proteoglycan found on solid tumors including pediatric liver cancers (GPC3-CAR)” NCT02932956 ↗ |